Tenaya Therapeutics, Inc.
TNYANasdaq
$0.82
↓ -2.5%Jul 17 close · end-of-day
Price
1Y↑ +13.4%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$177.2M
Enterprise Value
$96.3M
P/E
—
P/S
—
P/B
1.7
EV/EBITDA
—
PEG
—
FCF Yield
-36.5%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$83.0M
Free Cash Flow (TTM)
-$64.6M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-78.2%
ROIC
-268.1%
Debt / Equity
—
Net Cash
$80.9M
Return 1Y
-5.7%
Company profile
Tenaya Therapeutics, Inc. discovers, develops, and delivers therapies for heart disease in the United States. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hypertrophic cardiomyopathy (gHCM) and gDCM. It is also developing a small molecule inhibitor of histone deacetylase 6 for use in heart failure with preserved ejection fraction (HFpEF)
- CEO
- Faraz Ali
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 110
- Headquarters
- California
- Website
- tenayatherapeutics.com
Earnings
TNYA Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$225,000.00—
Diluted EPS-$0.09↓ -62.5%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$38.9M | -$72.8M | -$125.6M | -$131.2M | -$115.9M | -$93.3M |
| Net income | -$38.4M | -$72.7M | -$123.7M | -$124.1M | -$111.1M | -$90.6M |
| Diluted EPS | — | -$4.10 | -$2.76 | -$1.68 | -$1.31 | -$0.59 |
| Operating cash flow | -$35.4M | -$60.8M | -$104.4M | -$102.1M | -$90.5M | -$68.3M |
| Free cash flow | -$45.2M | -$85.9M | -$125.1M | -$103.3M | -$91.5M | -$68.9M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $0.00 | — | — | — | $225,000.00 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$30.8M | -$26.7M | -$24.7M | -$27.5M | -$24.1M | -$20.9M | -$20.8M | -$20.1M |
| Net income | -$29.4M | -$25.6M | -$23.8M | -$26.9M | -$23.3M | -$20.3M | -$20.2M | -$19.3M |
| Diluted EPS | -$0.34 | -$0.30 | -$0.27 | -$0.24 | -$0.14 | -$0.12 | -$0.09 | -$0.09 |
| Operating cash flow | -$23.6M | -$19.8M | -$18.4M | -$23.1M | -$15.6M | -$15.6M | -$13.9M | -$19.2M |
| Free cash flow | -$23.7M | -$20.0M | -$18.6M | -$23.5M | -$15.8M | -$15.6M | -$14.0M | -$19.2M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | -8917.8% |
| Net margin | — | — | — | — | — | — | — | -8565.3% |
Company news
Jul 15, 2026
Jun 29, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.